Brief: Heat Biologics Presents Positive Survival Benefit For Hs-110 In Combination With Nivolumab In Phase 2 Lung Cancer Trial At 2020 Asco Annual Meeting

Scorpius Holdings

29/05/2020 15:10

May 29 (Reuters) - Heat Biologics Inc  HTBX.O :
    * HEAT BIOLOGICS PRESENTS POSITIVE SURVIVAL BENEFIT FOR
HS-110 IN
COMBINATION WITH NIVOLUMAB IN PHASE 2 LUNG CANCER TRIAL AT 2020
ASCO ANNUAL MEETING
    * HEAT BIOLOGICS - DATA SHOWED SIGNIFICANT SURVIVAL BENEFIT
OBSERVED IN COHORT OF PREVIOUSLY TREATED, CPI NAÏVE PATIENTS
WITH ADVANCED NSCLC
    * HEAT BIOLOGICS - STATISTICALLY SIGNIFICANT SURVIVAL
BENEFIT WITH
MOS OF 42.1 MONTHS WAS OBSERVED IN PATIENTS WITH INJECTION SITE
REACTION
    * HEAT BIOLOGICS - PLANNING AN END-OF-PHASE 2 MEETING WITH
FDA TO
DISCUSS REGISTRATION TRIAL DESIGN

Source text for Eikon:  ID:nNDL4xDRqk 
Further company coverage:  HTBX.O 

 ((Reuters.Briefs@thomsonreuters.com;))